P1116: SAFETY, PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD) AND ACTIVITY OF THE HIGHLY SELECTIVE PHOSPHOINOSITIDE 3-KINASE INHIBITOR DELTA (PI3KΔ) INHIBITOR IOA-244 IN PATIENTS WITH...

por Carlostella, C., Lahn, M., Hammett, T., van der Veen, L., Johnson, Z., Pickering, C., Santoro, A.
Publicado 2022

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs

por Gelardi, T, Caputo, R, Damiano, V, Daniele, G, Pepe, S, Ciardiello, F, Lahn, M, Bianco, R, Tortora, G
Publicado 2008

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

por Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K.A., Giannelli, G.
Publicado 2019

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

por Deken, M.A., Niewola-Staszkowska, K., Peyruchaud, O., Mikulčić, N., Antolić, M., Shah, P., Cheasty, A., Tagliavini, A., Nizzardo, A., Pergher, M., Ziviani, L., Milleri, S., Pickering, C., Lahn, M., van der Veen, L., Di Conza, G., Johnson, Z.
Publicado 2023